admin – page 17 – eisai china lnc.-威尼斯人888

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) has announced that on july 26, 2017 (u.s. time), its u.s. subsidiary eisai inc. received approval from the u.s. food and drug administration (fda) for a supplemental new drug application (snda) for eisai’s antiepileptic drug (aed) fycompa (perampanel) as monotherapy use for the treatment of partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 12 years of age and older.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that the results of a phase iii trial (study 304) of its in-house discovered and developed anticancer agent lenvatinib mesylate (product names: lenvima® / kisplyx®, “lenvatinib”) against the comparator sorafenib as first-line treatment for unresectable hepatocellular carcinoma, will be orally presented during the 53rd annual meeting of the american society of clinical oncology (asco), taking place in chicago, the united states. in this study, lenvatinib was the first agent to demonstrate statistical non-inferiority against sorafenib in the primary endpoint of overall survival (os) and showed statistically significant and clinically meaningful improvements in the secondary endpoints of progression free survival (pfs), time to progression (ttp), and objective response rate (orr), doubling sorafenib‘s median values and ratios.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) has announced that it will grant a total of 500 million yen to the global health innovative technology fund (“ghit fund”) to fund the second phase of its activities, which will take place in the five-year period from fy 2018 to fy 2022. the ghit fund is a public-private partnership, co-established in april 2013 by multiple japanese pharmaceutical companies (including eisai), the japanese government, and the bill & melinda gates foundation, for the purpose of accelerating development of new medicines to cure infectious diseases in developing and emerging countries by facilitating collaboration between research organizations in japan and overseas.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that, approaching the 65th anniversary of its chocola bb brand, it will launch chocola bb® gold rich (designated quasi-drug), a supplement drink recommended to relieve fatigue, on monday, april 17.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has presented the latest research data regarding a mechanism of action that led to increased anti-tumor activity in mouse models which had been dosed with a combination of the in-house developed anticancer agent lenvatinib mesylate (lenvatinib) and an anti-mouse pd-1 antibody, at the american association for cancer research (aacr) 108th annual meeting.